TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.
Company Growth (employees)
San Diego, US
Size (employees)
118 (est)
TearLab was founded in 2003 and is headquartered in San Diego, US

TearLab Office Locations

TearLab has an office in San Diego
San Diego, US (HQ)
100 9980 Huennekens St

TearLab Data and Metrics

TearLab Financial Metrics

TearLab's revenue was reported to be $28 m in 2016
Numbers are in $, USD

Revenue (Y, 2016)

28 m

Revenue growth (Y, 2015 - Y, 2016), %


Gross profit (Y, 2016)

17.8 m

Gross profit margin (Y, 2016), %


EBIT (Y, 2016)

(16 m)

Market capitalization (24-May-2017)

10.9 m

Closing share price (24-May-2017)


Cash (31-Dec-2016)

15.5 m
TearLab's current market capitalization is $10.9 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015Y, 2016


14.6 m19.7 m25.2 m28 m

Revenue growth, %


Cost of goods sold

8.1 m8.8 m10.8 m10.2 m

Gross profit

6.5 m10.9 m14.3 m17.8 m

Gross profit Margin, %


Operating expense total

24.3 m44.7 m44.1 m31.7 m


(17.8 m)(25 m)(31.5 m)(16 m)

EBIT margin, %


Interest expense

(4 m)

Interest income

35 k28 k(2 m)

Net Income

(29 m)(23.7 m)(33.2 m)
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016


37.8 m16.3 m13.8 m15.5 m

Accounts Receivable

3.5 m2.5 m3 m2.3 m


885 k790 k1.2 m

Current Assets

42.9 m22.7 m21.6 m22.2 m

Total Assets

50 m31 m28.4 m26.6 m

Accounts Payable

631 k2.2 m2.3 m1.9 m

Current Liabilities

8.6 m6.4 m7.5 m5.9 m

Additional Paid-in Capital

477.2 m483.9 m488.5 m506.9 m

Retained Earnings

(435.8 m)(459.6 m)(492.8 m)(512.7 m)

Total Equity

41.4 m24.4 m(4.2 m)(5.7 m)

Financial Leverage

1.2 x1.3 x-6.7 x-4.7 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Depreciation and Amortization

1.5 m1.1 m

Accounts Receivable

742 k


780 k

Accounts Payable

(335 k)

Cash From Operating Activities

22.3 m(21.4 m)(2.5 m)

Cash From Financing Activities

38.5 m548 k24.6 m15.6 m

Interest Paid

2.3 m
Y, 2016

Financial Leverage

-4.7 x

TearLab Market Value History

TearLab Online and Social Media Presence

TearLab Company Life and Culture

You may also be interested in